Compare Stocks: BGM, SPRY, AVIR, and CGC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.15 -0.2%	$5.27	$2.87 ▼ $6.45	$413.45M	0.39	309,688 shs	157,967 shs
BGM BGM Group	$10.75 +7.9%	$8.39	$6.45 ▼ $303.00	$126.37M	1.85	6,232 shs	3,273 shs
CGC Canopy Growth	$0.83 -2.3%	$0.96	$0.81 ▼ $2.38	$380.47M	0.78	2.16 million shs	2.37 million shs
SPRY ARS Pharmaceuticals	$4.23 -7.2%	$5.13	$3.98 ▼ $13.15	$453.48M	0.85	1.58 million shs	1.26 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-0.19%	+0.39%	-2.28%	+3.21%	+66.13%
BGM BGM Group	+7.93%	+15.10%	+31.21%	+6.97%	-96.37%
CGC Canopy Growth	-2.33%	-5.52%	-13.84%	-14.84%	-45.94%
SPRY ARS Pharmaceuticals	-7.24%	+3.93%	-19.12%	-46.73%	-61.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.15 -0.2%	$5.27	$2.87 ▼ $6.45	$413.45M	0.39	309,688 shs	157,967 shs
BGM BGM Group	$10.75 +7.9%	$8.39	$6.45 ▼ $303.00	$126.37M	1.85	6,232 shs	3,273 shs
CGC Canopy Growth	$0.83 -2.3%	$0.96	$0.81 ▼ $2.38	$380.47M	0.78	2.16 million shs	2.37 million shs
SPRY ARS Pharmaceuticals	$4.23 -7.2%	$5.13	$3.98 ▼ $13.15	$453.48M	0.85	1.58 million shs	1.26 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-0.19%	+0.39%	-2.28%	+3.21%	+66.13%
BGM BGM Group	+7.93%	+15.10%	+31.21%	+6.97%	-96.37%
CGC Canopy Growth	-2.33%	-5.52%	-13.84%	-14.84%	-45.94%
SPRY ARS Pharmaceuticals	-7.24%	+3.93%	-19.12%	-46.73%	-61.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	35.92% Upside
BGM BGM Group	1.00	Sell	N/A	N/A
CGC Canopy Growth	2.20	Hold	N/A	N/A
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	491.02% Upside

Current Analyst Ratings Breakdown

Latest BGM, SPRY, AVIR, and CGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
8/26/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	SPRY ARS Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
8/12/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/6/2026	BGM BGM Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
7/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	AVIR Atea Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
BGM BGM Group	$37.92M	3.60	N/A	N/A	$121.05 per share	0.09
CGC Canopy Growth	$251.01M	1.48	N/A	N/A	$1.13 per share	0.73
SPRY ARS Pharmaceuticals	$116.93M	3.60	N/A	N/A	$1.16 per share	3.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
BGM BGM Group	-$19.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	-$190.29M	-$0.45	N/A	N/A	N/A	-65.33%	-21.91%	-14.34%	11/6/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest BGM, SPRY, AVIR, and CGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q2 2027	CGC Canopy Growth	-$0.03	N/A	N/A	N/A	$57.72 million	N/A
8/28/2026	Q2 2026	BGM BGM Group	N/A	-$0.30	N/A	-$0.0050	N/A	$12.15 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/7/2026	Q1 2027	CGC Canopy Growth	-$0.04	-$0.02	+$0.02	-$0.02	$58.21 million	$142.62 million
7/21/2026	Q4 2025	BGM BGM Group	N/A	-$80.70	N/A	-$2.6850	N/A	$11.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
BGM BGM Group	N/A	1.25	0.73
CGC Canopy Growth	0.31	3.04	2.39
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
BGM BGM Group	N/A
CGC Canopy Growth	3.33%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	21.60%
BGM BGM Group	58.66%
CGC Canopy Growth	0.35%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	55	80.21 million	62.88 million	Optionable
BGM BGM Group	471	12.69 million	5.25 million	N/A
CGC Canopy Growth	1,128	449.30 million	447.73 million	Optionable
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable

BGM, SPRY, AVIR, and CGC Headlines

Recent News About These Companies

Head to Head Analysis: ARS Pharmaceuticals (NASDAQ:SPRY) vs. Vanda Pharmaceuticals (NASDAQ:VNDA)

October 8 at 4:44 AM | americanbankingnews.com

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 5, 2026 | tmcnet.com

ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

October 5, 2026 | prnewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 5, 2026 | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

October 4, 2026 | newsfilecorp.comN

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 4, 2026 | newsfilecorp.comN

ARS Pharmaceuticals (NASDAQ:SPRY) & Sunshine Biopharma (NASDAQ:SBFM) Critical Survey

October 4, 2026 | americanbankingnews.com

SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 3, 2026 | newsfilecorp.comN

ARS PHARMACEUTICALS DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

October 3, 2026 | newsfilecorp.comN

ARS Pharmaceuticals Officer Eric Karas Files Form 144 to Sell 100,000 Shares on NASDAQ

October 2, 2026 | kalkinemedia.comK

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

October 2, 2026 | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

October 2, 2026 | globenewswire.com

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

October 2, 2026 | globenewswire.com

Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026

October 1, 2026 | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 1, 2026 | globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 1, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

October 1, 2026 | prnewswire.com

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 1, 2026 | prnewswire.com

Critical Survey: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)

October 1, 2026 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

October 1, 2026 | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00

October 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM, SPRY, AVIR, and CGC Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$5.15 -0.01 (-0.19%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$5.14 -0.01 (-0.10%)

As of 10/9/2026 07:30 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

BGM Group NASDAQ:BGM

$10.75 +0.79 (+7.93%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.44 -0.31 (-2.88%)

As of 10/9/2026 07:30 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Canopy Growth NASDAQ:CGC

$0.83 -0.02 (-2.33%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.84 +0.01 (+1.44%)

As of 10/9/2026 07:59 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

ARS Pharmaceuticals NASDAQ:SPRY

$4.23 -0.33 (-7.24%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.29 +0.06 (+1.39%)

As of 10/9/2026 07:30 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BGM, SPRY, AVIR, and CGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BGM, SPRY, AVIR, and CGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BGM, SPRY, AVIR, and CGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM, SPRY, AVIR, and CGC Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

BGM Group NASDAQ:BGM

Canopy Growth NASDAQ:CGC

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BGM, SPRY, AVIR, and CGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BGM, SPRY, AVIR, and CGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BGM, SPRY, AVIR, and CGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM, SPRY, AVIR, and CGC Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

BGM Group NASDAQ:BGM

Canopy Growth NASDAQ:CGC

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools